iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating)’s share price gapped down before the market opened on Tuesday . The stock had previously closed at $21.24, but opened at $20.35. iTeos Therapeutics shares last traded at $20.97, with a volume of 3,101 shares changing hands.
iTeos Therapeutics Stock Up 1.0 %
The firm has a 50 day moving average price of $19.38 and a two-hundred day moving average price of $20.94. The company has a market capitalization of $717.19 million, a price-to-earnings ratio of 2.90 and a beta of 1.45.
Institutional Trading of iTeos Therapeutics
Several large investors have recently modified their holdings of the business. Comerica Bank acquired a new position in iTeos Therapeutics in the first quarter worth about $523,000. Mutual of America Capital Management LLC acquired a new position in iTeos Therapeutics in the first quarter worth about $93,000. Victory Capital Management Inc. acquired a new position in iTeos Therapeutics in the first quarter worth about $1,203,000. Russell Investments Group Ltd. grew its stake in iTeos Therapeutics by 281.8% in the first quarter. Russell Investments Group Ltd. now owns 16,800 shares of the company’s stock worth $540,000 after purchasing an additional 12,400 shares in the last quarter. Finally, Texas Permanent School Fund acquired a new position in iTeos Therapeutics in the first quarter worth about $459,000. 94.71% of the stock is currently owned by institutional investors and hedge funds.
iTeos Therapeutics Company Profile
Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.
- Get a free copy of the StockNews.com research report on iTeos Therapeutics (ITOS)
- Microsoft Shares: Is it Time to Back Up the Truck?
- Three CBD Stocks to Dominate a Budding Industry
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Is the 60/40 Portfolio Mix Still in Vogue?
- Institutional Support for Analog Devices Remains High
Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.